Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

  1. August 09, 2022

    Amgen Looks To Duck Regeneron's Bundling Suit

    Pharmaceutical giant Amgen asked a Delaware federal court to throw out a suit from competitor Regeneron alleging that Amgen used a bundling scheme to boost its own cholesterol medication sales while ruining the market for Regeneron's competing product.

  2. May 31, 2022

    Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud

    Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.